Inhibrx Biosciences, Inc. INBX Lessee Operating Lease Liability Payments Due

Lessee Operating Lease Liability Payments Due at other companies

Nuvation BioNUVB

——

Replimune GroupREPL

——

ImmunityBio, Inc.IBRX

——

BridgeBio PharmaBBIO

——

Crinetics PharmaceuticalsCRNX

——

Other financials

Income statement

See full

Revenue--100%

Operating income-$30.9M+27.9%

Net income-$33.4M+22.8%

EPS (diluted)-$2.15+23.2%

Balance sheet

See full

Cash & equivalents$161.7M-25.3%

Total debt$180.9M+69.8%

Total equity-$21.0M-122%

Total assets$184.0M-24.2%

Cash flow

See full

Operating cash flow-$38.0M-5.9%

CapEx--100%

Free cash flow-$38.0M-5.9%

Valuation

See full

Market cap$1.4B+546%

Enterprise value$1.42B+1,233%

P/S1,073.7×-280×

Profitability

See full

Operating margin-10,386.5%-5,025pp

Net margin-10,773.5%-878,492pp

FCF margin-9,986.5%-4,727pp

Returns & leverage

See full

Return on equity-197.8%-2,158pp

Debt / equity13.4×+13.3×

Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s lessee operating lease liability payments due.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s lessee operating lease liability payments due?: Inhibrx Biosciences, Inc. (INBX) reported lessee operating lease liability payments due of $6.59M in Q1 2026.
How has Inhibrx Biosciences, Inc.'s lessee operating lease liability payments due changed year-over-year?: Inhibrx Biosciences, Inc.'s lessee operating lease liability payments due decreased by 28.8% year-over-year, from $9.26M to $6.59M.